800401-67-6

Basic information

• Product Name: ethyl 5-chloro-1H-pyrrolo[2,3-c]pyridine-2-carboxylate
• Synonyms: ethyl 5-chloro-1H-pyrrolo[2,3-c]pyridine-2-carboxylate;3-c]pyridine-2-carboxylate;ethyl 5-chloro-1H-pyrrolo[2;5-Chloro-6-azaindole-2-carboxylic acid ethyl ester;5-chloro-1H-Pyrrolo[2,3-c]pyridine-2-carboxylic acid ethyl ester
• CAS NO: 800401-67-6
• Molecular Formula: C₁₀H₉ClN₂O₂
• Molecular Weight: 224.64
• Product Categories: CHIRAL CHEMICALS
• Mol File: 800401-67-6.mol

Chemical Properties

• Boiling Point: 405.984 °C at 760 mmHg
• Flash Point: 199.332 °C
• Appearance: /
• Density: 1.391 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.637
• Storage Temp.: Inert atmosphere,Room Temperature
• PKA: 11.76±0.40(Predicted)
• CAS DataBase Reference: ethyl 5-chloro-1H-pyrrolo[2,3-c]pyridine-2-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl 5-chloro-1H-pyrrolo[2,3-c]pyridine-2-carboxylate(800401-67-6)
• EPA Substance Registry System: ethyl 5-chloro-1H-pyrrolo[2,3-c]pyridine-2-carboxylate(800401-67-6)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 800401-67-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Ethyl 5-chloro-1H-pyrrolo[2,3-c]pyridine-2-carboxylate is utilized as a key building block for the synthesis of various drug molecules. Its unique structure allows it to be a versatile component in the development of new pharmaceuticals, targeting a range of diseases and conditions.
Used in Drug Discovery and Development:
ethyl 5-chloro-1H-pyrrolo[2,3-c]pyridine-2-carboxylate serves as a valuable starting point for drug discovery and development efforts. Its interaction with biological targets and potential to modulate their activity makes it a candidate for further exploration in creating novel therapeutic agents.
Used in Medicinal Chemistry Research:
Ethyl 5-chloro-1H-pyrrolo[2,3-c]pyridine-2-carboxylate is employed in medicinal chemistry research to understand its pharmacological properties and to identify its potential medical uses. The ethyl ester group's influence on its hydrophobicity is a key aspect of these studies, as it can impact the compound's solubility and bioavailability, which are critical factors in drug design and efficacy.

InChI:InChI=1/C10H9ClN2O2/c1-2-15-10(14)7-3-6-4-9(11)12-5-8(6)13-7/h3-5,13H,2H2,1H3

Upstream product

• 867036-37-1 potassium (1Z)-1-(2-chloro-5-nitropyridine-4-yl)-3-ethoxy-3-oxoprop-1-en-2-olate 
• 23056-33-9 2-chloro-4-methyl-5-nitro-pyridine 
• 695-34-1 2-Amino-4-methylpyridine 
• 21901-40-6 2-amino-5-nitro-4-picoline 
• 800401-66-5 ethyl-3-(2-chloro-5-nitropyridin-4-yl)-2-oxopropanoate 

Downstream Products

• 867036-42-8 (5-chloro-1H-pyrrolo[2,3-c]pyridin-2-yl)methanol 
• 800401-68-7 5-chloro-1H-pyrrolo[2,3-c]pyridine-2-carboxylic acid 
• 920978-86-5 ethyl 5-chloro-1-[(3-fluorophenyl)methyl]-1H-pyrrolo[2,3-c]pyridine-2-carboxylate 
• 867036-45-1 5-chloro-1H-pyrrolo[2,3-c]pyridine-2-carboxaldehyde 
• 800402-01-1 5-chloro-1H-pyrrolo[2,3-c]pyridine-2-carboxylic acid [1-(S)-(tert-butyldimethylsilanyloxymethyl)-2-(S)-hydroxy-2-phenylethyl]amide 
• 800402-02-2 5-chloro-1H-pyrrolo[2,3-c]pyridine-2-carboxylic acid [1-(S)-(tert-butyldimethylsilanyloxymethyl)-2-oxo-2-phenylethyl]amide 
• 800401-99-4 5-chloro-1H-pyrrolo[2,3-c]pyridine-2-carboxylic acid [2-phenyl-1-(S)-(2-phenyl-[1,3]dioxolan-2-yl)ethyl]amide 
• 800397-99-3 5-chloro-1H-pyrrolo[2,3-c]pyridine-2-carboxylic acid[1-(S)-(4-fluorobenzyl)-2-(4-hydroxypiperidin-1-yl)-2-oxoethyl]amide 
• 800398-36-1 2-(S)-[(5-chloro-1H-pyrrolo[2,3-c]pyridine-2-carbonyl)amino]-3-phenylpropionic acid 

Relevant articles and documents

Synthesis of the new ring system bispyrido[4',3':4,5]pyrrolo [1,2-a:1',2'-d]pyrazine and its deaza analogue

Derivatives of the new ring systems bispyrido[4',3':4,5]pyrrolo[1,2-a:1',2'-d] pyrazine-6,13-dione and its deaza analogue pyrido[4",3":4',5']pyrrolo-[1',2':4,5]pyrazino [1,2-a]indole-6,13-dione were conveniently synthesized through a four-step sequence. Symmetrical derivatives of the former ring system were obtained through self condensation. On the other hand, condensation of 6-azaindole carboxylic acid with indole 2-carboxylic acid afforded the deaza analogue ring system. Derivatives of the title ring system were tested by the National Cancer Institute (Bethesda, MD, USA) and four of them exhibited modest activity against MCF7 (a breast cancer cell line) and/or UO-31 (a renal cancer cell line).

AZAINDOLES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS

Azaindoles having inhibitory activity on RSV replication and having the formula (I) compositions containing these compounds as active ingredient and processes for preparing these compounds and compositions.

N-(ARYLALKYL)-1H-PYRROLOPYRIDINE-2-CARBOXAMIDE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF

The invention concerns compounds of general formula (I), wherein n, the pyrrolopyridine ring, X, Z1, Z2, Z3, Z4, Z5 and W are as defined herein. The invention also concerns a method for preparing said compounds and their therapeutic use.

PYRROLOPYRIDINE-2-CARBOXYLIC ACID AMIDES

Compounds represented by Formula (I) or pharmaceutically acceptable salts thereof, are useful in the prophylactic or therapeutic treatment of diabetes, hyperglycemia, hypercholesterolemia, hyperinsulinemia, hyperlipidemia, hypertension, atherosclerosis or tissue ischemia e.g. myocardial ischemia, and as cardioprotectants.

G-PROTEIN COUPLED RECEPTOR AGONISTS

Compounds of Formula (I) or pharmaceutically acceptable salts or N-oxides thereof, are agonists of GPR116 and are useful for the treatment of obesity, and for the treatment of diabetes.

6-AZAINDOLE COMPOUND

A compound represented by the formula (I) wherein R1, R2, R3 and R6 are the same or different and each is a hydrogen atom or a substituent; one of R4 and R5 is a hydrogen atom and the other is a group represented by the formula: -C(=X)-R7 wherein X is N-O-R8 or N-NH-R9 wherein R8 and R9 are the same or different and each is a hydrogen atom or a group bonded via a carbon atom; and R7 is a hydrogen atom or a substituent, and the like and a salt thereof have a superior IκB kinase inhibitory activity, and useful as pharmaceutical agents such as agents for preventing or treating diabetes and the like.

PYRROLOPYRIDINE-2-CARBOXYLIC ACID HYDRAZIDES

Compounds of Formula (I) or pharmaceutically acceptable salts thereof, are inhibitors of glycogen phosphorylase and are useful in the prophylactic or therapeutic treatment of diabetes, hyperglycemia, hypercholesterolemia, hyperinsulinemia, hyperlipidemia, hypertension, atherosclerosis or tissue ischemia e.g. myocardial ischemia, or as cardioprotectants or inhibitors of abnormal cell growth.

PYRROLOPYRIDINE-2-CARBOXYLIC ACID AMIDE INHIBITORS OF GLYCOGEN PHOSHORYLASE

Compounds represented by Formula (I): or pharmaceutically acceptable salts thereof, are inhibitors of glycogen phosphorylase and are useful in the prophylactic or therapeutic treatment of diabetes, hyperglycemia, hypercholesterolemia, hyperinsulinemia, hyperlipidemia, hypertension, atherosclerosis or tissue ischemia e.g. myocardial ischemia, and as cardioprotectants.